Developed by Kenvue, the new formulation arrives as patient dissatisfaction with existing non-prescription pain management reaches a reported 75%. By merging two established ingredients into a single dose, the product eliminates the need for patients to coordinate staggered dosing schedules or manage multiple medications independently. Eight clinical studies confirmed that the combination outperforms either acetaminophen or naproxen sodium when taken separately.
In section Releases
FDA Approves First Over-the-Counter Dual-Action Pain Reliever
The U.S. Food and Drug Administration has approved Tylenol with Naproxen, the first and only over-the-counter medication to combine 650 mg of acetaminophen with 220 mg of naproxen sodium. This fixed-dose treatment aims to provide both rapid onset and 12-hour relief without the risks associated with opioid-based prescriptions.
Dr. Rajesh Mishra, Chief Medical Officer at Kenvue, noted that the treatment is designed to break the cycle of trial-and-error often associated with persistent pain. For clinicians, the approval offers a standardized, multimodal option that remains opioid-free. The FDA has granted a three-year exclusivity period for this specific OTC formulation, which is expected to reach major U.S. retailers in the coming months. Detailed clinical data supporting the product's efficacy is scheduled for presentation at the 2026 PAINWeek conference.
Comments (0)
No comments yet. Be the first!